Welcome to Innate Pharma

About Innate Pharma

Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients

See company profile

Headlines

Conference call, June 15, 2017

Agenda:
Acquisition of the anti-C5aR antibody (IPH5401)
IPH4102 data (results of the dose-escalation part of a Phase I trial presented at ICML on June 14, 2017)

Listen to the replay

Annual General Meeting

The Annual General Meeting took place on June 23, 2017, in Marseille, France.

Read the press release on AGM results

Conference call: 2016 financial statements

March 7th, 2017: Innate Pharma published its 2016 financial statements.
The management team held a conference call to the attention of institutional investors and sell-side analysts.

Listen to the replay

Download area

Corporate Presentation | Q3 2017

Download

Activity report 2016

Download

Reference Document 2016

Download

Science & products presentation 2016

Download

Welcome to Innate Pharma

About Innate Pharma

Headlines

Conference call, June 15, 2017

Annual General Meeting

Conference call: 2016 financial statements

Download area

Latest news

Issuance by Innate Pharma of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for rights in anti-C5aR

Results of Annual General Meeting and changes to Innate Pharma’s governance and management team

Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102

Upcoming events

ESMO 2017 | Madrid, Spain

EORTC Cutaneous Lymphoma Task Force | London, England

8th annual world ADC | San Diego, USA